Shattuck Labs (STTK) Gains from Investment Securities (2019 - 2026)
Shattuck Labs (STTK) reported Gains from Investment Securities of $262000.0 for Q1 2026, up 303.08% year-over-year from $65000.0 in Q1 2025, and up 303.08% on a QoQ basis from $65000.0 in Q1 2025.
Shattuck Labs (STTK) has 8 years of Gains from Investment Securities data on file, last reported at $262000.0 in Q1 2026.
- Quarterly Gains from Investment Securities rose 303.08% year-over-year to $262000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $262000.0 (up 231.65% YoY) and the FY2025 annual result came in at $65000.0, down 85.59% from the prior year.
- Gains from Investment Securities rose to $262000.0 in Q1 2026 per STTK's latest filing, from $65000.0 in the prior quarter.
- Across five years, Gains from Investment Securities topped out at $2.9 million in Q2 2022 and bottomed at -$2.9 million in Q3 2022.
- The 5-year median for Gains from Investment Securities is $39000.0 (2023), against an average of $92333.3.
- The widest annual swing landed in 2022, when Gains from Investment Securities slumped 1322.71%; it then jumped 1020.51% in 2024.
- Tracing STTK's Gains from Investment Securities over 5 years: stood at -$2.9 million in 2022, then soared by 100.48% to $14000.0 in 2023, then slumped by 71.43% to $4000.0 in 2024, then soared by 1525.0% to $65000.0 in 2025, then surged by 303.08% to $262000.0 in 2026.
- Per Business Quant, the three latest STTK Gains from Investment Securities figures stand at $262000.0 (Q1 2026), $65000.0 (Q1 2025), and $4000.0 (Q3 2024).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn |
| 10 | Shattuck Labs | 667.80 Mn | 667.80 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 262,000.00 |
| Mar 31, 2026 | 262,000.00 |
| Mar 31, 2025 | 65,000.00 |
| Mar 31, 2025 | 65,000.00 |
| Sep 30, 2024 | 4,000.00 |
| Sep 30, 2024 | 4,000.00 |
| Jun 30, 2024 | 10,000.00 |
| Jun 30, 2024 | 10,000.00 |
| Mar 31, 2024 | 437,000.00 |
| Mar 31, 2024 | 437,000.00 |
| Dec 31, 2023 | 14,000.00 |
| Dec 31, 2023 | 14,000.00 |
| Mar 31, 2023 | 39,000.00 |
| Mar 31, 2023 | 39,000.00 |
| Sep 30, 2022 | -2.95 Mn |
| Sep 30, 2022 | -2.95 Mn |
| Jun 30, 2022 | 2.95 Mn |
| Jun 30, 2022 | 2.95 Mn |
| Sep 30, 2021 | -207,000.00 |
| Sep 30, 2021 | -207,000.00 |
| Jun 30, 2021 | -960,000.00 |
| Jun 30, 2021 | -960,000.00 |
| Dec 31, 2020 | 181,000.00 |
| Dec 31, 2020 | 181,000.00 |
| Sep 30, 2020 | -28,000.00 |
| Sep 30, 2020 | -28,000.00 |
| Jun 30, 2020 | -97,000.00 |
| Jun 30, 2020 | -97,000.00 |
| Mar 31, 2020 | 61,000.00 |
| Mar 31, 2020 | 61,000.00 |
| Sep 30, 2019 | 10,000.00 |
| Sep 30, 2019 | 10,000.00 |